Monday, September 12, 2022

Krishna Institute of Medical Sciences Ltd (543308)-Entry into Nagpur market

Krishna Institute of Medical Sciences Ltd (543308) closes   at 1238.35 with  a   Loss of   -3.00%   on    12-September-2022  with formation of  a  Long Red   Candle    on Daily  Price Chart.

About the Company : Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1

Sector Update :  Positive

Refinitiv  Average Score : 09/ 10

Financials : Krishna Institute of Medical Sciences Ltd  has posted Net Sales / Revenue   of 1650.80 Cr & Net Profit of   332.70 Cr in FY2022 and expected to post Net Sales / Revenue   of 2213.80 Cr  & Net Profit of 334.60 Cr in FY2023, Net Sales / Revenue   of 2405.30 Cr  & Net Profit of 392.60 Cr in FY2024 and Net Sales / Revenue   of 2817.30 Cr  & Net Profit of 437.60 Cr in FY2025.

Valuations  : The Company is now Trading at X2.90 of its  valuations of  FY2022 (Last 4 Quarters ) earnings with ~290% premium ;  at X2.13 of its FY2023 earnings with ~213%  Premium and at X1.82 of its FY2024 earnings with ~182%  Premium .

EPS  will  improve from 41.60 in FY2022 to 54.70  in FY2025  and RoE from 29.60% to 20.40% during the same period.

Early Trend : Entring into Nagpur market.

MF/FII : ICICI PRUDENTIAL MUTUAL FUND A/C - ICICI PRUDENTIAL SMALLCAP FUND has bought it on 12.09.2022

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.40 which  makes is attractive after 60% decline .The  Equity Value Per Share ( Enterprise Value Method ) is  1216

If We factor its FY2025 earnings/valuations, its Price arrives at 2204.

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source NSE Website | Screener.In  | Capital Line Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D


Mahindra Lifespace Developers Ltd (532313) – Targeting a 2.5-fold jump in its annual sales bookings

Mahindra Lifespace Developers Ltd (532313)  closes   at 537.65 with  a   Gain of   +1.20%   on    on    09-September-2022  with formation of  a  Green   Candle    on Daily  Price Chart.

About the Company : Mahindra Lifespace Developers Ltd was incorporated in 1999, it is engaged in the business of development of the real estate, residential facilities, commercial complexes and through its subsidiary companies is involved in various infrastructure projects including the development of SEZs and Industrial Clusters.

Sector Update :  Positive

Refinitiv  Average Score : 06/ 10

Financials : Mahindra Lifespace Developers Ltd  has posted Net Sales / Revenue   of 393.60 Cr & Net Profit of   17.30  Cr in FY2022 and expected to post Net Sales / Revenue   of 766.30 Cr  & Net Profit of 131.80 Cr in FY2023  and Net Sales / Revenue   of 1017.10 Cr  & Net Profit of 166.00 Cr in FY2023  .

 

Valuations  : The Company is now Trading at X3.50 of its  valuations of  FY2022 (Last 4 Quarters ) earnings with ~350% premium ;  at X4.50 of its FY2023 earnings with ~450%  Premium and at X3.58 of its FY2024 earnings with ~358%  Premium .

EPS  will  improve from 1.10 in FY2022 to 10.7  in FY2023  and RoE from 13.90% to 16.20% during the same period.

Early Trend : Mahindra Lifespace Developers is looking to acquire a few land parcels this fiscal to build housing projects with sales potential of Rs 3,000-4,000 crore and targeting a 2.5-fold jump in its annual sales bookings to Rs 2,500 crore in the next three years.

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.30 which  makes is attractive after 70% decline .The  Equity Value Per Share ( Enterprise Value Method ) is  521

If We factor its FY2024 earnings/valuations, its Price arrives at 524.

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source NSE Website | Screener.In  | Capital Line Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 

 


Friday, September 9, 2022

Sikko Industries Ltd(SIKKO)- Business Objective changed to increase TOP Lines

Sikko Industries Ltd(SIKKO) closes   at 118.90 with  a   Gain of   +5.0%   on    on    09-September-2022  with formation of  a  Long Head   Candle    on Daily  Price Chart.

About the Company : Sikko Industries Limited is one of the leading Manufacturer and Supplier of Organic Agricultural Pesticides, Fungicides, Bio Fungicides, Plant Growth Promoters, NPK Fertilizers, Weedicides, HDPE Bottles and Flexible Pouches.Sector Update :  Positive

Refinitiv  Average Score : 05/ 10

Financials : Sikko Industries Ltd(SIKKO) has posted Net Sales / Revenue   of 51.03 Cr & Net Profit of   1.88 Cr in FY2022 and expected to post Net Sales / Revenue   of 58.02Cr  & Net Profit of 5.68 Cr in FY2023  .

Valuations  : The Company is now Trading at X1.80  of its  valuations of  FY2022 (Last 4 Quarters ) earnings with ~80% premium ;  at X1.68 of its FY2023 earnings with ~68%  Premium .

EPS  will  improve from 1.68  in FY2022 to 5.08  in FY2023 .

Early Trend : Cos. Is entering into manufacture, formulate, process, develop, refine, import, export, wholesale and/or retail trade all kinds of pharmaceuticals, surgical with surgical instruments, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare, Ayurvedic and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors,soups, broths and other restoratives or foods and also to deal in medicinal goods such as surgical instruments,

contraceptives, photographic goods, oils, perfumes, cosmetics, patent medicines, soaps, artificial limbs, hospital requisites, proprietary medicines, veterinary medicines and tinctures extracts and to carry on the business of vialling, bottling, repacking, processing of tablets, capsules, syrups, injections, ointments, etc. and also to carry on the business of chemists, druggists, buyers, sellers, agents, distributors and stockists of all kinds of pharmaceuticals and allied products.

Web Address : https://sikkoindia.com/

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.60  which  makes is attractive after 40% decline .The  Equity Value Per Share ( Enterprise Value Method ) is  118.70

If We factor its FY2023/24 earnings/valuations, its Price arrives at 161.

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source NSE Website | Screener.In  | Capital Line Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 


IOL Chemicals & Pharmaceuticals Ltd(524164)- Doubling revenue in next four years


IOL Chemicals & Pharmaceuticals Ltd(524164)  closes   at 381.75  with  a   Gain of   +2.6%   on    on    07-September-2022  with formation of  a  Green   Candle    on Daily  Price Chart.

About the Company : IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%

Sector Update :  Positive

Refinitiv  Average Score : 05/ 10

Financials : IOL Chemicals & Pharmaceuticals Ltd  has posted Net Sales / Revenue   of 2184.00 Cr & Net Profit of   166.0 Cr in FY2022 and expected to post Net Sales / Revenue   of 2450.00 Cr (+12%) & Net Profit of 221.72 Cr in FY2023  & Net Sales / Revenue   of 2630.00 ( +20.5%) Cr & Net Profit of 238.01Cr in FY2024.

Valuations  : The Company is now Trading at X1.70 of its  valuations of  FY2022 (Last 4 Quarters ) earnings with ~70% premium ;  at X0.75 of its FY2023 earnings with ~25%  Discount and at X0.70 of its FY2023 earnings with ~30%  Discount

EPS  will  improve from 22.80  in FY2022 to 44.450  in FY2024  .

Early Trend : As part of de-risking their business, Cos has started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio. It is spending Rs 100-150 crore in capex every year, and is adding production lines at its Barnala plant which is spread over 100 acres.

 

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.70   which  makes is attractive .The  Equity Value Per Share ( Enterprise Value Method ) is  358.00

If We factor its FY2023 earnings/valuations, its Price arrives at 928.00

 

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source NSE Website | Screener.In  | Capital Line Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 


Wednesday, September 7, 2022

Syngene International Ltd (539268) – Best to get benefit of Pharma Sector Move in Future

Syngene International Ltd (539268)  closes   at ₹565.00  with  a   fall  of  -2.40.00%   on    on    06-September-2022 with formation of  a  Red  Candle    on Daily  Price Chart.

About the Company : Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

Sector Update :  Positive

Financials : Syngene International Ltd has posted Net Sales / Revenue   of ₹2604.20 Cr & Net Profit of   ₹426.50 Cr in FY2022 and expected to post Net Sales / Revenue   of ₹3120.20 Cr & Net Profit of ₹541.40 Cr in FY2023  & Net Sales / Revenue   of ₹3744.10 Cr & Net Profit of ₹665.10 Cr in FY2024.

Valuations  : The Company is now Trading at X 5.3 of its  valuations of  FY2022 earnings with ~530% Dpremium  ;  at X3.63 of its FY2023 earnings with ~363%  Premium and at X2.80 of its FY2024 earnings with ~228%  premium.

EPS  will  improve from 10.60  in FY2022 to 14.60  in FY2024, ROE from 12.90 to 13.70    and RoCE from 11.70 to 15.20 during the same period

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.2  which  makes is overpriced .The  Equity Value Per Share ( Enterprise Value Method ) is  552.00

If We factor its FY2024 earnings/valuations, its Price arrives at ₹1041.60

 Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source NSE Website | Screener.In  | Capital Line Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 


Disclaimer

The recommendations made herein do not constitute an offer to sell or a solicitation to buy any of the securities mentioned. No representations can be made that the recommendations contained herein will be profitable or that they will not result in losses. Readers using the information contained herein are solely responsible for their actions. Information is obtained from sources deemed to be reliable but is not guaranteed as to accuracy and completeness. The above recommendations are based on the theory of Technical Analysis and do not reflect the fundamental validity of the Scrip. www.niftynext..com does 't take any Responsibility for any losses arising from using the Stocks Recommendations.
We( WWW.NIFTYNEXT.COM) are not Registered with Any Regulatory Body in India ie SEBI,NSE,BSE,AMFI or Any Otheres.


Blog Archive